Comparison · NCT03439514-sae
PF-07265803 (ARRY-371797) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. PF-07265803 (ARRY-371797) vs Placebo: serious adverse events. Trial comparisons, record NCT03439514-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03439514-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.25 | 0.142 | 0.402 | wilson | |
| Risk in group 2 | 0.568 | 0.409 | 0.713 | wilson | |
| Risk difference, group 1 minus group 2 | -0.318 | -0.499 | -0.0981 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.44 | 0.24 | 0.807 | log | |
| Odds ratio, group 1 over group 2 | 0.254 | 0.0966 | 0.668 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on PF-07265803 (ARRY-371797) than on Placebo | 3.15 | 2 | 10.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | PF-07265803 (ARRY-371797) | Participants were randomized to receive PF-07265803 400 mg (4\*100 mg tablets) twice daily (BID). | 10 | 40 | EG000 |
| Group 2 | Placebo | Participants were randomized to receive placebo matched to PF-07265803 BID. | 21 | 37 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline (Day1) up to a maximum of 208 weeks
Source ClinicalTrials.gov
Trial
- Title
- A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
- NCT number
- NCT03439514
- Phases
- PHASE3
- Conditions
- Dilated Cardiomyopathy, Lamin A/C Gene Mutation
- Interventions
- ARRY-371797 (PF-07265803), Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2024-01-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03439514?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03439514-sae